Indazolanonyl derivatives of benzopyrans

A pharmaceutical composition comprising a sufficient amount of a compound to activate potassium channels in a mammal in need thereof and a pharmaceutically acceptable carrier, wherein said compound is of the formula:

• ##STR9## wherein:
• R.sub.1 is C.sub.1-6 perfluoroalkoxy, C.sub.1-6 perfluoroalkyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxyl, C.sub.2-6 alkoxycarbonyl, nitro, cyano, halogeno, C.sub.1-6 alkylsulfonamido, C.sub.1-6 perfluoroalkylsulfonamido, amino, C.sub.2-6 alkanoylamino, C.sub.2-6 perfluoroalkanoylamino, C.sub.1-12 mono- or dialkylamino, C.sub.1-6 alkylsulfonyl, C.sub.6-12 arylsulfonyul, carboxyl, or C.sub.1-12 mono- or di-alkylcarbamoyl;
• R.sub.2 is hydrogen, C.sub.1-6 perfluoroalkoxy, C.sub.1-6 perfluoroalkyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxyl, C.sub.2-6 alkoxycarbonyl, nitro, cyano, halogeno, C.sub.1-6 alkylsulfonamido, C.sub.1-6 perfluoroalkylsulfonamido, amino, C.sub.2-6 alkanoylamino, C.sub.2-6 perfluoroalkanoylamino, C.sub.1-12 mono- or dialkylamino, C.sub.1-6 alkylsulfonyl, C.sub.6-12 arylsulfonyl, carboxy, or C.sub.1-12 mono- or di-alkylcarbamoyl;
• provided that at least one of R.sub.1 and R.sub.2 is a C.sub.1-6 perfluoroalkoxy group;
• R.sub.3 and R.sub.4, independent from each other, are C.sub.1-6 alkyl;
• either R.sub.5 is hydrogen, hydroxyl, C.sub.2-6 alkanoyloxy, C.sub.7-12 aroyloxy, carbamoyloxy, formyloxy, C.sub.2-6 alkoxycarbonyloxy, mono- or di-C.sub.2-12 alkylcarbamoyloxy, and R.sub.6 is hydrogen, or R.sub.5 and R.sub.6 together are a bond;
• R.sub.7 and R.sub.8, independent from each other, are selected from the following:
• C.sub.1-6 perfluoroalkoxy, C.sub.1-6 perfluoroalkyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxyl, C.sub.2-6 alkoxycarbonyl, nitro, cyano, halogeno, C.sub.1-6 alkylsulfonamido, C.sub.1-6 perfluoroalkylsulfonamido, amino, C.sub.1-6 alkanoylamino, C.sub.2-6 perfluoroalkanoylaminom, C.sub.1-12 mono- or dialkylamino, C.sub.1-6 alkylsulfonyl, C.sub.6-12 arylsulfonyl, carboxyl, C.sub.1-12 mono- or di-alkylcarbamoyl, or hydrogen;
• and R.sub.9 is hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkylcarbonyl or C.sub.2-6 alkylsulfonyl;
• or a pharmaceutically acceptable salt thereof.

A pharmaceutical composition comprising an antihypertensive amount of a compound of the formula:

• ##STR10## wherein:
• R.sub.1 is C.sub.1-6 perfluoroalkoxy, C.sub.1-6 perfluoroalkyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxyl, C.sub.2-6 alkoxycarbonyl, nitro, cyano, halogeno, C.sub.1-6 alkylsulfonamido, C.sub.1-6 perfluoroalkylsulfonamido, amino, C.sub.2-6 alkanoylamino, C.sub.2-6 perfluoroalkanoylamino, C.sub.1-12 mono- or dialkylamino, C.sub.1-6 alkylsulfonyl, C.sub.6-12 arylsulfonyl, carboxyl, or C.sub.1-12 mono- or di-alkylcarbamoyl;
• R.sub.2 is hydrogen, C.sub.1-6 perfluoroalkoxy, C.sub.1-6 perfluoroalkyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxyl, C.sub.2-6 alkoxycarbonyl, nitro, cyano, halogeno, C.sub.1-6 alkylsulfonamido, C.sub.1-6 perfluoroalkylsulfonamido, amino, C.sub.2-6 alkanoylamino, C.sub.2-6 perfluoroalkanoylamino, C.sub.1-12 mono-dialkylamino, C.sub.1-6 alkylsulfonyl, C.sub.6-12 arylsulfonyl, carboxyl, or C.sub.1-12 mono- or di-alkylcarbamoyl;
• provided that at least one of R.sub.1 and R.sub.2 is a C.sub.1-6 perfluoralkoxy group;
• R.sub.3 and R.sub.4, independent from each other, are C.sub.1-6 alkyl;
• either R.sub.5 is hydrogen, hydroxyl, C.sub.2-6 alkanoyloxy, C.sub.7-12 aroyloxy, carbamoyloxy, formyloxy, C.sub.2-6 alkoxycarbonyloxy, mono- or di-C.sub.2-12 alkylcarbamoyloxy, and R.sub.6 is hydrogen, or R.sub.5 and R.sub.6 together are a bond;
• R.sub.7 and R.sub.8, independent from each other, are selected from the following:
• C.sub.1-6 perfluoroalkoxy, C.sub.1-6 perfluoroalkyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxyl, C.sub.2-6 alkoxycarbonyl, nitro, cyano, halogeno, C.sub.1-6 alkylsulfonamido, C.sub.1-6 perfluoroalkylsulfonamido, amino, C.sub.1-6 alkanoylamino, C.sub.2-6 perfluoroalkanoylamino, C.sub.1-12 mono- or di-alkylamino, C.sub.1-6 alkylsulfonyl, C.sub.6-12 arylsulfonyl, carboxyl, C.sub.1-12 mono- or di-alkylcarbamoyl, or hydrogen;
• and R.sub.9 is hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkylcarbonyl or C.sub.2-6 alkylsulfonyl;
• or a pharmaceutically acceptable salt thereof.